RESUMO
Low grade serous ovarian cancer (LGSOC) is a slowly growing, relatively chemoresistant neoplasm that is associated with a more favorable prognosis, especially compared to the disease's high-grade serous counterpart. We recount a case involving a 47-year-old, heavily pretreated LGSOC patient who presented with an elevated CA-125 of 1047â¯U/mL during her recent course of pemetrexed therapy. Thereafter, she underwent molecular profiling, which revealed a BRAF V600E mutation; accordingly, the patient was administered dabrafenib and trametinib combination therapy, a regimen that resulted in a precipitous decline of her CA-125 to 35â¯U/mL following the 6th cycle. The patient's favorable response to BRAF and MEK 1/2 inhibitor therapy underscores the significance of molecular profile testing and the use of targeted therapy regardless of tissue origin, especially in cases for whom standard management is limited or ineffective.
RESUMO
A hypersensitivity reaction attributed to platinum-based chemotherapy is a relatively common occurrence. Hyperthermic intraperitoneal chemotherapy potentially facilitates the safe retreatment of platinum therapy following this complication. We describe 3 ovarian cancer patients who were successfully retreated with carboplatin via hyperthermic intraperitoneal chemotherapy following hypersensitivity reaction.
Assuntos
Antineoplásicos/administração & dosagem , Carboplatina/administração & dosagem , Recidiva Local de Neoplasia/tratamento farmacológico , Neoplasias Ovarianas/tratamento farmacológico , Antineoplásicos/efeitos adversos , Carboplatina/efeitos adversos , Terapia Combinada , Hipersensibilidade a Drogas/prevenção & controle , Feminino , Humanos , Hipertermia Induzida , Infusões Parenterais/métodos , Pessoa de Meia-Idade , Neoplasias Ovarianas/cirurgia , RetratamentoAssuntos
Antineoplásicos/efeitos adversos , Enterostomia/efeitos adversos , Ácidos Hidroxâmicos/efeitos adversos , Perfuração Intestinal/etiologia , Neoplasias Ovarianas/tratamento farmacológico , Neoplasias Ovarianas/cirurgia , Feminino , Humanos , Perfuração Intestinal/diagnóstico , Perfuração Intestinal/terapia , Pessoa de Meia-Idade , VorinostatRESUMO
BACKGROUND: Uterine leiomyomas are typically considered benign lesions. Despite aggressive management, they can be unpredictable and eventually exhibit disease recurrence several years following initial treatment. CASE REPORT: We report a case involving a 55-year-old woman who was treated for a uterine leiomyoma at an outside medical institution 20 years ago. In November 2009, she presented to our gynecologic oncology service with a complex mass. Following surgery, the patient was diagnosed with a 16 cm ovarian mass and a synchronous leiomyosarcoma; the latter neoplasm appeared to originate from a previously resected uterine leiomyoma. CONCLUSIONS: The coexistence of these two lesions is exceedingly rare. We suspect that the leiomyosarcoma developed from either the patient's original uterine leiomyoma or leiomyomatosis peritonealis disseminata.